ArticleClinical & experimental metastasis2016
Brain metastases as site of first and isolated recurrence of breast cancer: the role of systemic therapy after local treatment.
Article in Clinical & experimental metastasis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 25 citations in OpenAlex.
- Central Nervous System Metastases in Breast Cancer.Current treatment options in oncology · 2025Review
- Role of antibody drug conjugates in the treatment of patients with breast cancer brain metastases.Therapeutic advances in medical oncology · 2024Review
- Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.Current treatment options in oncology · 2023Review
- A network meta-analysis of curative effect of different treatment methods on patients with brain metastasis of breast cancer.Medicine · 2022Article
- Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy.Cancers · 2022Review
- Clinicopathological characteristics and prognosis of breast cancer patients with isolated central nervous system metastases in the multicentre ESME database.Therapeutic advances in medical oncology · 2022Article
- Salvage resection of recurrent previously irradiated brain metastases: tumor control and radiation necrosis dependency on adjuvant re-irradiation.Journal of neuro-oncology · 2021Article
- Advances in the management of breast cancer brain metastases.Neuro-oncology advances · 2021Review
- A solitary brain metastasis as the only site of recurrence of HR positive, HER2 negative breast cancer: a case report and review of the literature.Journal of medical case reports · 2021Review
- Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review.CNS oncology · 2020Review
- Subtype switching in breast cancer brain metastases: a multicenter analysis.Neuro-oncology · 2020Article
- Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis.Breast cancer research and treatment · 2020Article
- Can anticancer chemotherapy promote the progression of brain metastases?Medical oncology (Northwood, London, England) · 2018Article
- Efficacy and pharmacodynamics of niraparib in BRCA-mutant and wild-type intracranial triple-negative breast cancer murine models.Neuro-oncology advancesArticle
- Impressive Long-term Response with Pertuzumab and Trastuzumab in HER2-positive Breast Cancer with Brain Metastasis.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of systemic treatment was assessed after local therapy for breast cancer patients who developed central nervous system (CNS) metastases as a first and isolated recurrence. Subjects were 128 breast cancer patients with brain metastases as the first and isolated site of recurrence that were selected from 673 consecutive breast cancer patients with brain metastases treated at the same institution. Median survival from brain metastases in patients with and without systemic treatment after local therapy was respectively 15 and 4 months (p < 0.001). In patients with a Karnofsky Performance Status ≥70 and those <70, survival was respectively 16 and 5.5 months (p < 0.001). The median survival from brain metastasis in patients with solitary brain metastasis, with and without systemic treatment after local therapy, was respectively 22 and 7 months (p = 0.003). Cox multivariate analysis demonstrated that good performance status, solitary brain metastasis and systemic therapy undertaken after local treatment were factors which prolonged survival. However patient survival was adversely affected by those having leptomeningeal metastasis associated with brain parenchymal lesions. Systemic therapy, undertaken after local treatment improved survival in those patients with breast cancer and brain metastases as the site of first and isolated recurrence. Further study is required in order to fully establish the role of systemic treatment for this patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.